Anti-bdca2 antibody
AssigneeSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
InventorsHaomin HUANG, Lan DENG, Jing LOU
Life of this patent
Estimating the term…
Abstract
Provided is an anti-BDCA2 antibody. The anti-BDCA2 antibody is capable of binding to the BDCA2 antigen with high specificity, exhibits high affinity, effectively inhibits CpG-A-stimulated secretion of IFNα and IgM by PBMCs, showing potential as a therapeutic agent for autoimmune diseases.
Claims15
An antibody or antigen-binding fragment thereof that binds to BDCA2, comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises heavy chain complementarity determining regions H-CDR1, H-CDR2, and H-CDR3, wherein
- the amino acid sequence of H-CDR1 is as shown in SYX1IH (SEQ ID NO:
- 30),
- the amino acid sequence of H-CDR2 is as shown in TIYPGX2GDTSYNQKFKG (SEQ ID NO:
- 31),
- the amino acid sequence of H-CDR3 is as shown in MGDNEYFDY (SEQ ID NO:
- 8), and
- the light chain variable region comprises light chain complementarity determining regions L-CDR1, L-CDR2, and L-CDR3;
- wherein,
- the amino acid sequence of L-CDR1 is as shown in RASGNIHNYLA (SEQ ID NO:
- 9),
- the amino acid sequence of L-CDR2 is as shown in DAETLAX3 (SEQ ID NO:
- 32),
- the amino acid sequence of L-CDR3 is as shown in QHFWSTPYT (SEQ ID NO:
- 11);
- wherein, X1 is I or L;
- X2 is an amino acid selected from the group consisting of:
- N, G, A, S, R;
- and/or X3 is an amino acid selected from the group consisting of:
- D, I, or E.
A CAR construct, wherein the scFv segment of the monoclonal antibody antigen-binding region of the CAR construct is a binding region that specifically binds to BDCA2, and the heavy chain variable region of the scFv comprises:
- heavy chain complementarity determining regions H-CDR1, H-CDR2, and H-CDR3, wherein
- the amino acid sequence of H-CDR1 is as shown in SYIIH (SEQ ID NO:
- 6), the amino acid sequence of H-CDR2 is as shown in TIYPGNGDTSYNQKFKG (SEQ ID NO:
- 7), the amino acid sequence of H-CDR3 is as shown in MGDNEYFDY (SEQ ID NO:
- 8), and
- the light chain variable region of the scFv comprises:
- light chain complementarity determining regions L-CDR1, L-CDR2, and L-CDR3, wherein the amino acid sequence of the L-CDR1 is as shown in RASGNIHNYLA (SEQ ID NO:
- 9), the amino acid sequence of L-CDR2 is as shown in DAETLAD (SEQ ID NO:
- 10), the amino acid sequence of L-CDR3 is as shown in QHFWSTPYT (SEQ ID NO:
- 11);
- wherein any one of the aforementioned amino acid sequences further optionally comprises a derivative sequence that optionally undergoes addition, deletion, modification, and/or substitution of at least one amino acid and is capable of retaining BDCA2 binding affinity.
Dependencies are inferred from the claim text.